X4 Pharmaceuticals to Present at September Investor Conferences
X4 Pharmaceuticals (NASDAQ: XFOR), a company dedicated to enhancing the lives of those with rare immune system diseases, has announced its participation in three significant investor conferences this September 2024. This presents an excellent opportunity for the company to connect directly with investors and share their latest developments in therapies.
Upcoming Conferences
Morgan Stanley 22nd Annual Global Healthcare Conference
The first event on the agenda is the Morgan Stanley 22nd Annual Global Healthcare Conference, set for Wednesday, September 4, 2024. Company management will engage in a fireside chat and conduct one-on-one meetings, offering a chance to explore the company's strategies and future outlook in greater detail.
Wells Fargo Healthcare Conference
Next, X4 Pharmaceuticals will attend the Wells Fargo Healthcare Conference on Thursday, September 5, 2024. This event will focus exclusively on one-on-one meetings, allowing for in-depth discussions with potential investors about the company’s mission and ongoing projects.
Cantor Fitzgerald Global Healthcare Conference
Lastly, X4 Pharmaceuticals will be part of the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 17, 2024. Similar to the Morgan Stanley event, this conference will feature a fireside chat along with one-on-one meetings, providing an interactive platform to discuss the company’s innovative therapies.
Webcast Availability
For those who cannot attend in person, live webcasts for both the Morgan Stanley and Cantor Fitzgerald conferences will be available through the investor relations section of X4 Pharmaceuticals’ official website. After the events, recordings of the webcasts will be accessible, ensuring that all interested parties can stay updated on the discussions.
Investment and Company Overview
X4 Pharmaceuticals is dedicated to making strides for patients by focusing on the development and commercialization of groundbreaking therapies for rare diseases related to the immune system, which have significant unmet medical needs. Leveraging their expertise in CXCR4 biology and the immune system, X4 has successfully developed mavorixafor, marketed as XOLREMDI™. This medication has received approval in the United States for its initial indication, with plans to explore its use for additional indications, thereby reaching more patients in need.
Conclusion
The upcoming investor conferences serve as a vital platform for advancing discussions about X4 Pharmaceuticals’ initiatives in rare disease therapies. They provide crucial opportunities for management to engage with investors, highlight their pipeline, and share insights into the company's strategic direction.
Frequently Asked Questions
What is X4 Pharmaceuticals focusing on during the conferences?
X4 Pharmaceuticals will highlight their advancements in therapies for rare immune system diseases and discuss their strategic initiatives.
When is the Morgan Stanley conference taking place?
The Morgan Stanley 22nd Annual Global Healthcare Conference is scheduled for September 4, 2024.
How can investors access the webcasts of the conferences?
The webcasts will be accessible through the investor relations section of X4 Pharmaceuticals’ website during and after the events.
What innovative therapy has X4 Pharmaceuticals developed?
X4 Pharmaceuticals has developed mavorixafor, which is approved in the United States under the brand name XOLREMDI™.
How can investors schedule one-on-one meetings with the company?
Interested investors should reach out to their respective Morgan Stanley, Wells Fargo, or Cantor Fitzgerald representatives to arrange meetings with the company management.
